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OBJECTIVES The purpose of the study was to investigate the role of nitric oxide (NO) in monocyte-
endothelial interaction by augmenting NO release via transfection of human endothelial cells
(ECs) with EC NO synthase (eNOS) DNA.
BACKGROUND Enhancement of NO synthesis by L-arginine or shear stress reduces endothelial adhesiveness
for monocytes and inhibits atherogenesis. To elucidate further the underlying mechanism, we
augmented NO synthase expression by transfection of human EC.
METHODS Liposome-mediated transfection of EC was performed with a plasmid construct containing
the gene encoding eNOS. Expression of eNOS was confirmed by reverse transcription–
polymerase chain reaction (RT-PCR). Endothelial cells were exposed to human monocytoid
cells, and adherent cells were quantitated using a computer-assisted program. Nitric oxide was
measured by chemiluminescence.
RESULTS The NO levels were not different in EC that were either not transfected, transfected with
beta-gal or liposomes only. The nitric oxide synthase (NOS) transfection increased NO
release by 160% (n 5 6), which increased further when EC were stimulated by shear stress
(24 h) by 1137% (n 5 5) as compared with untransfected, unstimulated EC (both p , 0.05).
The RT-PCR revealed diminished monocyte chemotactic protein-1 (MCP-1) expression in
eNOS transfected EC. There was an inverse relation between NO levels and monocyte
binding (r 5 20.5669, p , 0.002). Stimulation of EC with tumor necrosis factor-alpha
(TNF-alpha; 250 U/ml) led to a decrease in NO synthesis, and an increase in monocyte
binding. Cells transfected with NOS were resistant to both effects of TNF-alpha.
CONCLUSIONS Endothelial cells transfected with eNOS synthesize an increased amount of NO; this is
associated with diminished MCP-1 expression and monocyte-endothelial binding. The
reduction in monocyte-endothelial binding persists even after cytokine stimulation. (J Am
Coll Cardiol 1999;34:1201–7) © 1999 by the American College of Cardiology
Accumulating evidence indicates that endothelium-derived
nitric oxide (NO) is a potent inhibitor of endothelial
interaction with monocytes (1–8). The effect of NO to
inhibit endothelial adhesiveness for monocytes appears to
have an acute and a delayed mechanism. The NO donors
acutely inhibit monocyte adherence to the endothelium, an
effect mimicked by cyclic guanosine monophosphate
(cGMP) analogues (1). The acute effect of exogenous or
endogenous NO to inhibit monocyte adhesion occurs in the
absence of any change in endothelial adhesion molecules for
monocytes (5). It is possible that the acute effect of NO on
monocyte-endothelial interaction is mediated by a cGMP-
dependent inhibition of adhesion signaling. However, a
sustained exposure to NO donors, or to increased NO
biosynthesis, appears to inhibit monocyte binding by alter-
ing the expression of endothelial adhesion molecules and
chemokines. Endothelial cells exposed to cytokines or oxi-
dized lipoprotein elaborate superoxide anion (3,4). This
endothelial oxidative stress is associated with activation of
nuclear factor kB (NFkB) and its translocation to the
nucleus, where it activates the expression of vascular cell
adhesion molecule (VCAM), monocyte chemotactic protein
(MCP) and other gene encoding proteins involved in
endothelial-monocyte interaction (4,6–8). Nitric oxide
turns off this oxidant-sensitive transcriptional pathway by
reducing endothelial generation of superoxide anion, and by
increasing the expression of IkBa, the cytoplasmic inhibitor
of NFkB (4,6–9). In this study we set out to provide
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additional evidence for the important role of NO in
monocyte-endothelial interaction by augmenting NO re-
lease via transfection of human endothelial cells with endo-
thelial cell (EC) nitric oxide synthase (eNOS) DNA.
METHODS
Transfection. Transformed human umbilical vein endo-
thelial cells (ECV 304) were transfected at 70% to 80%
confluency with eNOS DNA (eNOS DNA: T. Michel,
Harvard Medical School; pUC-CAGGS expression plas-
mid: J. Miyazaki, Tokyo; engineered vector: H. von der
Leyen) or pSV40-beta-gal reporter plasmid (beta-gal; neg-
ative control) mediated by cationic liposomes (Lipo-
fectamine, Gibco BRL). Once cells reached confluency
(approx. 96 h after transfection) the medium was changed to
serum-free M199. After 1 h of incubation, cells were either
exposed to static or flow conditions and in some experi-
ments stimulated with cytokines (tumor necrosis factor-
alpha [TNF-alpha] for 4 h; 250 U/ml; Sigma).
Expression of eNOS, MCP-1 and GAPDH mRNA.
ISOLATION OF RNA. Total cellular RNA was isolated from
VSMC (10) using the Total RNA Extraction Kit (Promega,
Madison, Wisconsin). The RNA concentration and purity
were controlled spectrophotometrically by the optical den-
sity measured at 260/280 nm. RNA was diluted in RNAse-
free water and kept at 270°C. The samples of RNA used
for reverse transcription–polymerase chain reaction (RT-
PCR) were treated with DNASe (1 U/mg of RNA) for
15 min at 37°C, followed by phenol-chloroform extraction
of RNA from digestion mixture.
PRIMERS. The eNOS-specific primers (see Table 1), local-
ized in exon 12 (sense) and exon 16 (antisense), were used
to generate 422 base pairs (bp) product. Because of the
similarity of the cDNA sequence, the primers were able to
amplify both the human and bovine endothelial NOS. The
primers for human MCP-1 (Table 1) were localized in
exons 1 and 3, and generated 256 bp product. Primers for
the human glyceraldehyde phosphate dehydrogenase
(housekeeping, reference gene; Table 1) were used to
produce 587 bp product as a control for RNA isolation and
amplification.
REVERSE TRANSCRIPTION–POLYMERASE CHAIN REACTION
(RT-PCR). A qualitative analysis of mRNA expression was
performed by RT-PCR assay, using 500 ng of total RNA
obtained from cells collected 48 h after transfection (includ-
ing the 24-h shear stress treatment). A 30-min reverse
transcription step was performed at 70°C (1 U Tth DNA
polymerase, 1 mmol/liter MnCl2, 1 mmol/liter downstream
[39] primer). Afterwards, 20 ml of chelating buffer
(750 mmol/liter EGTA, 0.5 U Taq polymerase, 2.5 mmol/
liter MgCl2, 250 nmol/liter upstream [59] primer) was
added and 30 cycles of PCR were performed (94°C/40 s,
62°C/40 s, 72°C/40 s). Final elongation step was 10 min at
72°C. The amplification was performed in a thermocycler
(MJ Research Inc., Waltham, Massachusetts). The PCR
products were analyzed electrophoretically on ethidium
bromide-stained 2% agarose gel.
REAGENTS. Total RNA Extraction kit, Tth polymerase and
Taq polymerase were purchased from Promega. RNAse-
free DNAse and agarose were from Gibco BRL. The
primers were synthesized by Keystone Laboratories (Menlo
Park, California).
FLUID FLOW. Flow was induced by placing culture dishes
on a mixing table (Thermylene) rotating at 120 rpm for
24 h. Compared with the well-defined cone-plate viscom-
eter, this technique induces qualitatively similar changes in
cell alignment, NO production and NOS mRNA transcrip-
tion (4,5,10).
NITRIC OXIDE MEASUREMENT. Following exposure to ei-
ther static conditions or stimulation with flow or cytokines,
medium was collected from each well for measurements of
the stable breakdown products NO2 and NO3 (2). In brief,
nitrogen oxides are measured with a commercially available
Abbreviations and Acronyms
ANOVA 5 analysis of variance
EC 5 endothelial cells
eNOS 5 endothelial cell nitric oxide synthase
MCP-1 5 monocyte chemotactic protein-1
NFkB 5 nuclear factor kB
NO 5 nitric oxide
NOS 5 nitric oxide synthase
RT-PCR 5 reverse transcription–polymerase chain
reaction
TNF-a 5 tumor necrosis factor-alpha
VCAM 5 vascular cell adhesion molecule
Table 1. eNOS and MCP-1 Specific Primers
Primer Sequence
eNOS sense 59CTG ATG GCC AAG CGA GTG AA
eNOS antisense 59CCC AGT CCG AAC ACA CAG AA
MCP-1 sense 59TGC CTG CTG CTC ATA GCA GCC
MCP-1 antisense 59GTT TGC TGT TCC AGG TGG TCC
GAPDH sense 59CGT ATT GGG CGC CTG GTC ACC
GAPDH antisense 59GGG ATG ATG TTC TGG AGA GCC C
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chemiluminescence apparatus (model 2108, Dasibi, Glen-
dale, California), after reduction of the samples in boiling
acidic vanadium (III) chloride at 98°C. Boiling acidic
vanadium quantitatively reduces the oxidative metabolites of
NO (NO2 and NO3) to NO, which is quantified by the
chemiluminescence detector after reaction with ozone. Sig-
nals from the detector were analyzed by a computerized
integrator and recorded as areas under the curve. Standard
curves for NaNO2/NaNO3 were linear over the range of 50
pmol/liter to 10 nmol/liter.
FUNCTIONAL BINDING ASSAY. Endothelial adhesiveness for
monocytes was assessed with a functional binding assay as
we have previously described (5). Briefly, confluent mono-
layers of venous endothelial cells were washed with HBSS
(Irvine Scientific, Santa Ana, California) containing (in
mmol/liter) CaCl2 2, MgCl2 2 and HEPES 20. Culture
dishes were then placed on a rocking platform, and human
monocytoid cells (THP-1) were incubated with ECVs for
30 min, with dishes rotated 120° clockwise every 10 min to
ensure even distribution of cells. Medium was aspirated and
replaced with fresh HBSS to remove nonadherent cells.
After a second washing, dishes were returned to the rocker
platform for an additional 5 min. Medium was again
aspirated and replaced with HBSS containing 2% glutaral-
dehyde. After overnight fixation, adherent mononuclear
cells were quantitated using a computer analysis program
(Image Analyst, Billerica, Massachusetts).
STATISTICAL ANALYSES. Data reported are expressed as a
percentage of values obtained in the control group (i.e.,
untransfected, unstimulated cells), which represent 100%.
For all statistical tests, differences were considered statisti-
cally significant if the two-sided probability of the observed
result under the null hypothesis was #0.05. Results are
expressed as mean value 6 SD. All calculations were
performed using SPSS (SPSS, Chicago, Illinois). Analysis
of variance (ANOVA) was performed to identify a signifi-
cant difference among the mean values of a variable mea-
sured in more than two groups. When the ANOVA was
significant, comparisons of the mean values were made by a
paired Student t test with the Fisher exact test correction.
Correlation coefficients were calculated by Pearson product-
moment correlation.
RESULTS
Efficiency of transfection. To assess the efficiency of
transfection, ECs transfected with the beta-gal construct
were stained by X-gal 96 h after the transfection (at the time
point at which the data described below were collected).
After exposure to X-gal, the EC monolayer was assessed by
light microscopy. Approximately 20% to 30% of EC were
stained by X-gal, which is consistent with the range of
transfection efficiencies typically achieved using cationic
liposomal technique in vitro.
All EC expressed eNOS mRNA, as demonstrated by
RT-PCR (Fig. 1). However, the expression of eNOS was
higher in cells transfected with eNOS plasmid than in cells
transfected with beta-galactosidase gene or treated with
liposomes (Fig. 1).
To rule out that eNOS product in eNOS-transfected cells
were not derived from amplification of plasmid DNA,
samples were treated with RNAse-free DNAse before
RT-PCR. The RT-PCR performed on RNA isolated after
such a digestion revealed the presence of eNOS mRNA in
transfected cells (Fig. 2).
The transfection procedure itself did not affect the pa-
rameters of endothelial biology assessed in this study.
Specifically, we observed no difference in NO synthesis or
endothelial adhesiveness for monocytes in nontransfected
cells, cells exposed only to the cationic liposome solution or
cells exposed to the mixture of cationic liposomes and the
beta-gal plasmid construct (data not shown).
NO release and monocyte binding. Endothelial cells
transfected with eNOS exhibited an increase (158 6 19%;
n 5 6) in NO production in comparison to nontransfected
Figure 1. Expression of eNOS and GAPDH mRNA in ECV cells. Note the augmented eNOS expression in eNOS-transfected cells.
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cells (n 5 7) or -gal-transfected cells (99 6 2%; n 5 2) (all
p , 0.05) (Fig. 3). When nontransfected EC were exposed
to shear stress, an increase in NO biosynthesis was observed
(134 6 27%, n 5 6) in comparison to quiescent conditions.
When EC transfected with eNOS were also exposed to
shear stress there was a greater increase in NO levels
observed (237 6 78%; n 5 5; p , 0.05) compared with
quiescent nontransfected cells.
These results were mirrored by those obtained from
monocyte-endothelial binding assays. Transfection with
eNOS tended to reduce endothelial adhesiveness for mono-
cytes (91 6 6%; n 5 2), compared with the untransfected,
unstimulated cells (100%; n 5 2) or the beta-gal-transfected
group (102 6 2; n 5 2; p 5 NS) (Fig. 4). When
nontransfected EC were exposed to a 24-h period of shear
stress (before the binding assay), their adhesiveness declined
significantly compared with quiescent conditions (78 6
16%; n 5 2). The effect of shear stress was even more
pronounced in the eNOS-transfected cells (70 6 3% of
values achieved in nontransfected cells exposed to quiescent
conditions, p , 0.05).
Furthermore, ECV cells treated with liposomes or
pSVbeta-gal plasmid expressed higher amounts of MCP-1
mRNA than did eNOS-transfected cells (Fig. 5), suggest-
ing that augmented NO generation by eNOS-transfected
cells induces downregulation of MCP-1 expression and thus
decreased adhesion of monocytes to eNOS-transfected EC.
To ensure that these observations with NOS gene trans-
fection were not unique to this cell line, these studies were
repeated using transformed murine brain EC (bEnd3 cells)
and murine monocytoid cells (WEHI 274.1). In the murine
EC we also observed a significant increase in NO release in
eNOS-transfected cells (146% of the response in nontrans-
fected cells; n 5 2). The eNOS-transfected murine EC also
manifested a greater increase in NO release when exposed to
shear stress (198%; n 5 4 p , 0.05). This was associated
Figure 2. RT-PCR for eNOS mRNA was performed on the same
RNA isolation before and after its digestion with RNAse-free
DNAse. The PCR product was obtained in both cases, which
indicates the presence of eNOS mRNA in the transfected cells.
Figure 3. Histogram showing effect of eNOS transfection on NO production. The eNOS-transfected cells manifest a significant increase
in basal NO production, which is further augmented by exposure to shear stress. Control 5 nontransfected cells; beta-gal 5 cells
transfected with a plasmid construct encoding the gene for NO synthase; SS 5 control cells exposed to shear stress; eNOS 1 SS 5 eNOS
cells exposed to shear stress. *p , 0.05 vs. control and b-gal.
Figure 4. Histogram showing effect of eNOS transfection on
endothelial monocyte binding. Transfection with eNOS reduced
monocyte-endothelial binding in comparison to untransfected
control cells or beta-gal transfected cells. Monocyte-endothelial
binding was further inhibited by prior exposure of endothelial cells
to shear stress (all p , 0.05). *p , 0.05 vs. control and beta-gal.
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with reduced monocyte binding to eNOS-transfected cells
(223%; p , 0.05).
NO release and monocyte binding after cytokine stimu-
lation. In the following series of experiments, EC were
incubated with tumor necrosis factor-alpha (TNF-alpha)
96 h after transfection. Exposure to TNF-alpha reduced
levels of NO synthesis in cells that were transfected with
beta-gal to a level of NO production (82 6 12%) of control
cells (Fig. 6). The effect of TNF-alpha was reversed by prior
transfection with eNOS (108 6 8% of the NO elaborated
by nontransfected cells not exposed to TNF-alpha). There
was a significant difference in NO synthesis between eNOS
and beta-gal-transfected cells (p , 0.02).
These results were again mirrored by data obtained from
monocyte binding studies. The TNF-alpha stimulation led
to an increase in monocyte binding in beta-gal-transfected
cells (134 6 19%; n 5 6) but not in the eNOS-transfected
cells (94 6 9%; n 5 2; p , 0.02) (Fig. 7).
Bivariate correlation. Data obtained from monocyte bind-
ing assays and NO measurements were entered into a
bivariate correlation analysis; a significant inverse correla-
tion was detected between NO release and monocyte
binding (r 5 20.5669; p , 0.002).
DISCUSSION
The salient findings of this investigation are:
1. The eNOS transfection increased NO elaboration by
transformed human umbilical venous endothelial cells in
quiescent and shear-stress conditions;
2. The enhancement of NO synthesis was associated with
reduced endothelial adhesiveness for monocytes; and
3. The eNOS transfection increased the resistance of EC to
cytokine-induced adhesion.
In the current study, we have demonstrated that human
umbilical venous EC or murine brain EC generate more
NO when transfected with a plasmid construct encoding
NOS. The increase in NO generation was associated with a
diminished MCP-1 expression and a reduction of endothe-
lial adhesiveness for monocytes. In the NOS-transfected
cells, shear stress produced a greater rise in NO elaboration,
consistent with previous observations that the tractive force
of fluid flow activates endothelial NOS (5,11,12). The
combination of shear stress and eNOS overexpression had
additive effects to suppress monocyte adhesion. This latter
observation may be due to the fact that, in addition to
enhancing NO release, shear stress may have NO-
independent effects to reduce endothelial adhesiveness
(13,14). Cells transfected with NOS were resistant to the
effects of TNF-alpha to induce endothelial adhesiveness for
monocytes. These findings are consistent with previous
observations that NO inhibits endothelial-monocyte inter-
action (1,3–8).
Our findings are in keeping with previous observations
indicating that modulation of endogenous NO synthesis
Figure 5. Expression of MCP-1 mRNA in ECV cells. Note the diminished MCP-1 expression in eNOS-transfected cells.
Figure 6. TNF-alpha stimulation reduced NO production in those cells transfected with beta-gal but not in those transfected with eNOS
(p , 0.02). *p , 0.02 vs. b-gal 1 TNF-a.
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affects endothelial monocyte interaction and atherogenesis.
It has recently been shown that a circulating antagonist of
NOS is elevated in the presence of atherosclerosis or risk
factors for atherosclerosis (15–19). This competitive inhib-
itor of NOS is asymmetric dimethylarginine, the effects of
which can be reversed by supplemental L-arginine (15,19–
21). The diminution of NO activity not only affects vascular
tone but also affects endothelial-monocyte interaction. Ex-
ogenous administration of NO synthase antagonists to New
Zealand White rabbits increases endothelial adhesiveness
for monocytes, and accelerates atherogenesis (2,9,11,12,15–
24). Endothelial cells exposed to NOS antagonists generate
less NO, and more superoxide anion (25). This may be
because NO normally suppresses oxidative enzyme activity
(9).
The imbalance between NO and superoxide anion leads
to activation of an oxidant-sensitive transcriptional pathway
that induces the expression of endothelial adhesion mole-
cules and chemokines mediating monocyte adherence
(3,4,6–8). This atherogenic pathway can be abrogated by
enhancing endogenous NO production (23,24). New Zea-
land White rabbits fed a 1% cholesterol diet for 10 weeks
develop intimal lesions that involve 40% of the thoracic
aortae; administration of supplemental L-arginine enhances
endothelial synthesis of NO, reduces MCP-1 elaboration
and inhibits lesion formation by 75% (3,26,27).
The vessel wall will be a likely target for gene therapy in
the future. Because of its strategic location, the endothelium
may be genetically engineered to have local effects on the
vessel wall; to condition circulating blood elements; or to
secrete substances into the lumen so as to have systemic
effects. To date, most experimental applications have been
targeted to affect vessel structure, particularly to inhibit
restenosis after balloon angioplasty. These approaches have
included the use of antisense oligonucleotides to inhibit
genes involved in vascular smooth muscle proliferation (28);
oligonucleotide “decoys” to neutralize transcriptional factors
involved in cell cycle (29); or plasmid constructs encoding
“vasoprotective” genes that enhance endothelial regenera-
tion or vascular generation of NO (30). Gene therapy
directed at enhancement of endothelial regeneration and
angiogenesis may also prove fruitful in the treatment of
atherosclerosis and restenosis (31,32). Indeed, in vivo
adenovirus-mediated endovascular delivery of neuronal NO
synthase has been most recently shown to enhance vascular
NOS activity and to reverse hyperlipidemia-induced vascu-
lar dysfunction (33).
Conclusions. Transfection of cultured EC with a plasmid
construct encoding the endothelial isoform of NOS in-
creases the elaboration of NO by quiescent or shear-stressed
cells. The increase in NO elaboration reduced endothelial
adhesiveness for monocytes, and increased the resistance of
the endothelium to cytokine-stimulated monocyte adhe-
sion.
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